Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies
- 17 December 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 58 (5), 659-672
- https://doi.org/10.1007/s40262-018-0725-7
Abstract
Bruton tyrosine kinase (BTK) is a key component of B-cell receptor signalling, critical for cell proliferation. Acalabrutinib, a selective, covalent BTK inhibitor, recently received an accelerated approval in relapsed/refractory mantle cell lymphoma. This analysis characterized the population pharmacokinetics (PK) of acalabrutinib and its metabolite ACP-5862.Keywords
This publication has 14 references indexed in Scilit:
- Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency ProfileThe Journal of pharmacology and experimental therapeutics, 2017
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2016
- Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patientsBritish Journal of Clinical Pharmacology, 2015
- Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignanciesAnnals of the New York Academy of Sciences, 2015
- Targeting Bruton's tyrosine kinase in B cell malignanciesNature Reviews Cancer, 2014
- Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling MethodsCPT: Pharmacometrics & Systems Pharmacology, 2013
- Likelihood based approaches to handling data below the quantification limit using NONMEM VIJournal of Pharmacokinetics and Pharmacodynamics, 2008
- Mechanism-Based Concepts of Size and Maturity in PharmacokineticsAnnual Review of Pharmacology and Toxicology, 2008
- Mechanisms of B-cell lymphoma pathogenesisNature Reviews Cancer, 2005
- Lymphoid Malignancies: the dark side of B-cell differentiationNature Reviews Immunology, 2002